高脑微出血负荷急性缺血性卒中患者静脉溶栓的获益
本研究通过多步算法建模,评估脑微出血负荷≤10与>10的急性缺血性卒中患者接受或不接受静脉溶栓的90天改良Rankin量表评分。结果显示,>10个微出血患者静脉溶栓与良好功能结局的比值比点估计降低7%至10%但仍>1,且显著增加死亡几率;在高龄、卒中严重及治疗延迟较长的患者中,净治疗效应倾向于不溶栓。因>10个微出血的总体检验前概率低(0.6%-2.7%),仅当磁共振成像延迟溶栓<10分钟时,治疗前量化微出血负荷才合理。
要点
- >10个脑微出血患者静脉溶栓仍与良好功能结局相关,但获益降低且死亡风险增加。
- 高龄、严重卒中及治疗延迟长的>10个微出血患者,净治疗效应倾向于不溶栓。
- >10个微出血的检验前概率低(0.6%-2.7%),仅当磁共振成像不延迟溶栓>10分钟时才考虑筛查。
核心结论
- 高脑微出血负荷修饰静脉溶栓的治疗效应,>10个微出血患者溶栓与更高死亡率和特定亚组的净效用损失相关。
研究设计与样本
- 采用多步算法建模,参数提取自近期发表的荟萃分析,模拟≤10与>10个脑微出血患者接受或不接受静脉溶栓的90天改良Rankin量表评分。
主要发现
- >10个微出血患者接受静脉溶栓与良好结局(改良Rankin量表≤2)的比值比点估计较≤10个微出血患者低7%至10%,但范围仍为1.03-1.51。
- >10个微出血患者接受静脉溶栓显著增加死亡几率。
- >10个微出血患者静脉溶栓的净治疗效应(效用加权改良Rankin量表评分变化)点估计在高龄、卒中更严重及治疗延迟更长的患者中倾向于不溶栓。
关键数值与推荐
- >10个脑微出血的总体检验前概率为0.6%-2.7%。
- 仅当治疗前磁共振成像量化微出血负荷延迟静脉溶栓<10分钟时,该筛查才合理。
临床怎么用
- 对>10个脑微出血患者,应结合年龄、卒中严重程度和治疗延迟个体化评估静脉溶栓的净获益。
- 不推荐常规治疗前磁共振成像筛查微出血,除非能确保延迟静脉溶栓<10分钟。
局限性
- 参数来源于荟萃分析而非原始患者数据,模型结果需前瞻性验证。
- 原文未报告建模的具体假设和不确定性分析细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Cerebral microbleeds (CMBs) are a risk factor for intracranial hemorrhage. Whether intravenous thrombolysis (IVT) improves functional outcome in acute ischemic stroke patients with CMBs is unknown. We aimed to estimate the treatment effect of IVT in patients with acute ischemic stroke and a high burden (>10) of CMBs. Methods- We devised a multistep algorithm to model 90-day modified Rankin Scale scores in patients with ≤10 versus >10 CMBs who do or do not receive IVT. Parameters were extracted from recently published meta-analyses and included pairwise relationships between CMBs, IVT, 3-month functional outcome, and intracranial hemorrhage. Uncertainty was quantified in probabilistic sensitivity analyses. Results- In patients with >10 CMBs as compared with ≤10 CMBs, point estimates of the odds ratios for favorable outcome (modified Rankin Scale ≤2) associated with IVT were 7% to 10% lower but still >1 (range, 1.03-1.51). On the other hand, IVT in patients with >10 CMBs significantly increased the odds of mortality. The point estimates for the net treatment effect of IVT (change in the utility-weighted modified Rankin Scale score) in patients with >10 CMBs were in favor of withholding IVT in older patients with more severe strokes and longer treatment delays. However, because the general pretest probability of >10 CMBs is low (0.6%-2.7%), pretreatment magnetic resonance imaging to quantify CMB burden would be justified only if it delayed IVT by <10 minutes. Conclusions- High CMB burden modifies the treatment effect of IVT. In patients with >10 CMBs, IVT is associated with higher mortality and, in older patients with severe strokes and longer treatment delays, a net utility loss. Patients with higher-than-average pretest probability of >10 CMB might profit from magnetic resonance imaging screening if it does not increase the treatment time.
引用
- Schlemm L, Endres M, Werring DJ, et al. Benefit of Intravenous Thrombolysis in Acute Ischemic Stroke Patients With High Cerebral Microbleed Burden. Stroke. 2019. PMID: 31739772. doi:10.1161/STROKEAHA.119.027633
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。